StockTipsArenaBeta

BUY Camlin Fine Sciences Limited — Axis Securities

BUYCamlin Fine Sciences Limited
Camlin Fine Sciences share price target & all analyst calls

byAxis SecuritiesHorizon: NA (inferred 1 year)27 May 2026via Institutional / Brokerage Research

Entry₹130.19Inferred
Target₹170
Total upside +30.58%
Stop lossNot given
CMP₹76.031d ago
Active-41.60%+123.60%upside left 7 mo left
Follow Axis Securities for new calls(69% target hit, 843 closed calls)Get alertsWatch CAMLINFINE for new buy/sell callsGet alertsSee 2 other Long-term calls on CAMLINFINESee 542 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:24 pm IST
4 supporting2 neutral1 opposing
Supports the BUY call (4)

The company board approved a proposal to raise funds through the issuance of equity shares.

NSE · Outcome of Board Meeting·3 Nov · 4d ago

(opens in new tab)

Camlin Fine Sciences Limited announced a rights issue of equity shares for an amount not exceeding 250 crores, alongside its financial results for the quarter ended September 30, 2026.

NSE · Outcome of Board Meeting·3 Nov · 4d ago

(opens in new tab)

The company's board approved a rights issue of equity shares for an amount not exceeding Rs 250 crores. The board also released unaudited financial results for the quarter ended September 30, 2026.

BSE · Board Meeting·3 Nov · 4d ago

(opens in new tab)
Neutral / worth noting (2)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·6 Nov · yesterday

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Camlin Fine Sciences

All analyst calls on Camlin Fine Sciences

More from Axis Securities

Every call and its outcome